Asceneuron
Switzerland - LausanneBiotechnology
Focus: Asceneuron is a Swiss biotech focused on tauopathies and Alzheimer's disease, currently advancing lead candidate ASN51 through Phase 2 development. The company operates at Series C+ stage with a concentrated pipeline targeting high-unmet-need neurology indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Open Jobs
0
About Asceneuron
AI assessmentNot HiringNo open roles listed right now. Follow Asceneuron to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ASN51
Alzheimer DiseaseClinical Trials (5)
NCT06677203Study of ASN51 in Adults With Early Alzheimer's Disease
Phase 2Help build intelligence for Asceneuron
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.